Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 49.58 Billion KRW | -50.5% |
| 2022 | 100.17 Billion KRW | 63.84% |
| 2021 | 61.14 Billion KRW | -40.88% |
| 2020 | 103.41 Billion KRW | 25.47% |
| 2019 | 82.42 Billion KRW | 27.65% |
| 2018 | 64.56 Billion KRW | -26.5% |
| 2017 | 87.84 Billion KRW | 2.49% |
| 2016 | 85.7 Billion KRW | 4227.07% |
| 2015 | -2.07 Billion KRW | -161.38% |
| 2014 | 3.38 Billion KRW | -17.05% |
| 2013 | 4.07 Billion KRW | 579.67% |
| 2012 | -850.33 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 46.09 Billion KRW | -7.05% |
| 2024 Q2 | 62.71 Billion KRW | 36.08% |
| 2023 Q4 | 49.58 Billion KRW | 11.81% |
| 2023 FY | 49.58 Billion KRW | -50.5% |
| 2023 Q1 | 58.85 Billion KRW | -41.25% |
| 2023 Q2 | 35.67 Billion KRW | -39.39% |
| 2023 Q3 | 44.34 Billion KRW | 24.33% |
| 2022 FY | 100.17 Billion KRW | 63.84% |
| 2022 Q2 | 82.08 Billion KRW | 30.56% |
| 2022 Q1 | 62.87 Billion KRW | 2.83% |
| 2022 Q4 | 100.17 Billion KRW | 16.3% |
| 2022 Q3 | 86.13 Billion KRW | 4.94% |
| 2021 Q3 | 59.46 Billion KRW | 10.22% |
| 2021 Q4 | 61.14 Billion KRW | 2.82% |
| 2021 Q2 | 53.95 Billion KRW | -56.2% |
| 2021 Q1 | 123.17 Billion KRW | 19.75% |
| 2021 FY | 61.14 Billion KRW | -40.88% |
| 2020 Q4 | 102.85 Billion KRW | 21.86% |
| 2020 FY | 103.41 Billion KRW | 25.47% |
| 2020 Q3 | 84.4 Billion KRW | -21.63% |
| 2020 Q2 | 107.7 Billion KRW | 4.1% |
| 2020 Q1 | 103.46 Billion KRW | 26.13% |
| 2019 Q1 | 56.53 Billion KRW | -12.44% |
| 2019 Q2 | 77.92 Billion KRW | 37.84% |
| 2019 Q3 | 76.2 Billion KRW | -2.2% |
| 2019 Q4 | 82.02 Billion KRW | 7.64% |
| 2019 FY | 82.42 Billion KRW | 27.65% |
| 2018 FY | 64.56 Billion KRW | -26.5% |
| 2018 Q4 | 64.56 Billion KRW | -4.85% |
| 2018 Q3 | 67.85 Billion KRW | -0.43% |
| 2018 Q2 | 68.14 Billion KRW | 11.43% |
| 2018 Q1 | 61.16 Billion KRW | -30.38% |
| 2017 Q2 | 94.73 Billion KRW | 26.45% |
| 2017 Q1 | 74.92 Billion KRW | -12.59% |
| 2017 FY | 87.84 Billion KRW | 2.49% |
| 2017 Q4 | 87.84 Billion KRW | -10.38% |
| 2017 Q3 | 98.02 Billion KRW | 3.47% |
| 2016 Q3 | 66.31 Billion KRW | 443.84% |
| 2016 Q1 | 4.96 Billion KRW | 338.88% |
| 2016 FY | 85.7 Billion KRW | 4227.07% |
| 2016 Q2 | 12.19 Billion KRW | 145.8% |
| 2016 Q4 | 85.7 Billion KRW | 29.25% |
| 2015 FY | -2.07 Billion KRW | -161.38% |
| 2015 Q4 | -2.07 Billion KRW | -67.01% |
| 2015 Q3 | -1.24 Billion KRW | 8.36% |
| 2015 Q2 | -1.35 Billion KRW | 6.56% |
| 2015 Q1 | -1.45 Billion KRW | -142.92% |
| 2014 Q1 | 4.58 Billion KRW | 12.49% |
| 2014 Q3 | 4.76 Billion KRW | -22.78% |
| 2014 Q4 | 3.38 Billion KRW | -28.96% |
| 2014 FY | 3.38 Billion KRW | -17.05% |
| 2014 Q2 | 6.16 Billion KRW | 34.43% |
| 2013 Q3 | 6.22 Billion KRW | 18.43% |
| 2013 Q1 | 7.22 Billion KRW | 950.22% |
| 2013 FY | 4.07 Billion KRW | 579.67% |
| 2013 Q2 | 5.25 Billion KRW | -27.29% |
| 2013 Q4 | 4.07 Billion KRW | -34.48% |
| 2012 FY | -850.33 Million KRW | 0.0% |
| 2012 Q4 | -850.33 Million KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 207.364% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 222.175% |
| BINEX Co., Ltd. | 45.34 Billion KRW | -9.343% |
| Bioneer Corporation | -3.9 Billion KRW | 1368.857% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -493.697% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -234.705% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -451.432% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 303.0% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 87.252% |
| Peptron, Inc. | 4.86 Billion KRW | -918.444% |
| Amicogen, Inc. | 125.26 Billion KRW | 60.416% |
| Genexine, Inc. | 61.39 Billion KRW | 19.238% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 462.279% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 188.459% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 7.44% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 250.536% |
| SillaJen, Inc. | -13.89 Billion KRW | 456.937% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 41.167% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | -81.131% |
| Genomictree Inc. | -43.43 Billion KRW | 214.157% |
| MedPacto, Inc. | -64 Billion KRW | 177.475% |
| D&D Pharmatech | -7.5 Billion KRW | 760.436% |
| EASY BIO,Inc. | 53.21 Billion KRW | 6.815% |
| GI Innovation, Inc. | -4.82 Billion KRW | 1128.185% |